Why is the cheese sandwich the downfall of AI carb counting, even with “3D scanning”?
A slightly rhetorical question, I’ll admit, but a pertinent one. Once again, I have been trying out the latest (read most heavily pushed on Facebook […]
Articles by admin
The Libre Duo. A platform prototype to move care from the hospital to the home?
Abbott has put glucose and ketones on the same wearable, and the launch coverage is all about DKA. Worth having if you’re on a pump, which is fine as far as it goes, but it misses the bit that makes this interesting. Because if you look at what Abbott has actually built across its other divisions, and what they’ve patented alongside it, the Libre Duo doesn’t really look like a ketone sensor. It looks like the platform prototype and the first visible piece of an infrastructure designed to move chronic disease care out of outpatients and into the home. And the policy environment for that shift has just been locked in on both sides of the Atlantic for the next five years.
Five AI models, three users, one finding: the settings came from the textbook, not the data
We took Nightscout data from three people and gave it to 5 Large Language Models with a detailed prompt to see how they would respond.
The results weren’t what I was expecting.
I Asked AI to Count My Carbs 27,000 Times. It Couldn’t Give Me the Same Answer Twice.
Ask ChatGPT to estimate the carbs in your lunch. Now ask it again. And again. Five hundred times. You’d expect the same answer each time. […]
The Daily Bolus: The Triple Agonist Showdown & Surprising GLP-1 Wins in Type 1 Diabetes
Welcome to today’s edition of The Daily Bolus! The incretin landscape is rapidly evolving into the era of the “triple agonist,” with Eli Lilly and […]
100% Insulin Independence: Why Eledon’s Breakthrough is a Pillar, Not a Cure
Eledon Pharmaceuticals recently achieved 100% insulin independence in an early-phase islet transplant trial using its anti-CD40L drug, tegoprubart. It’s a massive step forward in transplant immunology that avoids the toxicity of standard drugs. But why isn’t it a cure yet, and how does it fit into the actual blueprint of a functional cure?
Explore a Decade of Diabetes Insights with Diabettech AI
After 10+ years of documenting the diabetes landscape, Diabettech is launching diabettech.ai—a custom research tool designed to help you navigate a decade’s worth of articles and reports. Powered by an LLM interface, this tool allows you to “interrogate” the site’s data to find specific answers on everything from cures to n=1 observations.
Key highlights of the beta launch:
Targeted Accuracy: Built to stick strictly to Diabettech articles and comments to minimize “hallucinations.”
Research-Focused: Optimized as a precision tool rather than a standard chatbot to provide relevant article links.
Sustainable Design: Privately funded and optimized for efficiency to manage resource costs and query speeds.
Ready to dive into the archives? Visit diabettech.ai to start your research and share your feedback on the beta experience.
The Daily Bolus: Red Cell Sponges, Microbiome Signatures, and Cyborg Cells
Today’s research is moving beyond the traditional “big three” of glucose disposal—liver, muscle, and fat. We explore how red blood cells can be recruited as metabolic “sponges,” how AI-driven gut signatures are catching insulin resistance earlier than ever, and why an electronic “cyborg” mesh might be the key to making lab-grown pancreatic cells finally function like the real thing. It’s a steady shift toward an integrated, multi-system approach to metabolic health.
Now We Know What a Type 1 Cure Could Look Like
The Type 1 cure is no longer theoretical. Human data now points to a blueprint: working cells, immune evasion, and durable immune modulation.
The Daily Bolus: Retinopathy Pills, Diabetes Risk Watches, and Immune Fixes for Insulin Resistance
The diabetes pipeline is starting to look a lot like the cardiovascular playbook: prevent early, intervene earlier, and push treatment upstream before irreversible damage begins. […]